At the time of writing, the cannabis company’s shares are fetching for 5.9 cents, down 1.67%.
Q3 FY21 quarterly update
Investors appear unfazed by the company’s latest snapshot, sending Zelira shares slightly in the negative.
According to its release, Zelira delivered a robust performance for the quarter ending 31 March 2021.
Cash receipts including product sales and licensing payment rose to a record $225,000, reflecting a 249% increase on H1 FY21. The strong growth predominately came from the company’s United States launch of its SprinjeneCBD oral care product in December.
Zelira noted that…